Drug Type AAV based gene therapy |
Synonyms AAV9 gene therapy containing codon optimized human FIG4 cDNA coding sequence (Elpida Therapeutics), AAV9-hFIG4 (Elpida Therapeutics), ELP-02 + [1] |
Target |
Action modulators |
Mechanism FIG4 modulators(FIG4 phosphoinositide 5-phosphatase modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Charcot-Marie-Tooth Disease, Type 4j | Phase 2 | - | 01 Apr 2026 |





